Tonix Pharmaceuticals Holding Corp. Stock Rating Reaffirmed by Zacks (TNXP)
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)‘s stock had its “outperform” rating restated by Zacks in a research note issued on Monday. They currently have a $16.00 price target on the stock. Zacks‘s target price suggests a potential upside of 20.94% from the stock’s previous close.
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up 4.31% during mid-day trading on Monday, hitting $13.8001. 153,102 shares of the company’s stock traded hands. Tonix Pharmaceuticals Holding Corp. has a 1-year low of $3.00 and a 1-year high of $21.00. The stock has a 50-day moving average of $12.31 and a 200-day moving average of $11.79. The company’s market cap is $137.0 million.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its earnings data on Friday, August 8th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.53) by $0.08. Analysts expect that Tonix Pharmaceuticals Holding Corp. will post $-2.01 EPS for the current fiscal year.
To view Zacks’ full report, visit Zacks’ official website.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.